Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug;15(7):385-95.
doi: 10.1111/hiv.12132. Epub 2014 Feb 24.

Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions

Affiliations

Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions

J L Marcus et al. HIV Med. 2014 Aug.

Abstract

Objectives: Adherence is critical for maximizing the effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV infection. Strategies for promoting adherence to HIV treatment, and their potential application to PrEP adherence, have received considerable attention. However, adherence promotion strategies for prevention medications have not been well characterized and may be more applicable to PrEP. We aimed to identify adherence support interventions that have been effective in other prevention fields and could be applied in the HIV prevention context to support pill taking among PrEP users.

Methods: To identify adherence support interventions that could be evaluated and applied in the PrEP context, we conducted a systematic review across the following prevention fields: hypertension, latent tuberculosis infection, hyperlipidaemia, oral contraceptives, osteoporosis, malaria prophylaxis, and post-exposure prophylaxis for HIV infection. We included randomized controlled trials that evaluated the efficacy of interventions to improve adherence to daily oral medications prescribed for primary prevention in healthy individuals or for secondary prevention in asymptomatic individuals.

Results: Our searches identified 585 studies, of which 48 studies met the eligibility criteria and were included in the review; nine evaluated multiple strategies, yielding 64 separately tested interventions. Interventions with the strongest evidence for improving adherence included complex, resource-intensive interventions, which combined multiple adherence support approaches, and low-cost, low-intensity interventions that provided education or telephone calls for adherence support.

Conclusions: Our review identified adherence interventions with strong evidence of efficacy across prevention fields and provides recommendations for evaluating these interventions in upcoming PrEP studies.

Keywords: HIV; antiretroviral medications; medication adherence; pre-exposure prophylaxis (PrEP); preventive therapy; review.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Identified studies of interventions to support adherence to daily oral medications prescribed in healthy or asymptomatic populations
Eligibility criteria were as follows: 1) randomized controlled trial; 2) at least one adherence outcome; 3) designed to support adherence to a daily oral medication in healthy or asymptomatic populations; 4) conducted in the following clinical fields: hypertension, latent tuberculosis infection, hyperlipidemia, oral contraceptives to prevent pregnancy, osteoporosis, malaria prophylaxis, and post-exposure prophylaxis for HIV infection.
Figure 2
Figure 2. Risk of bias among included studies (N=48)
“Other bias” included bias potentially introduced by using different adherence measures across intervention groups, not accounting for clustering in analysis, contamination of the control group, not accounting for baseline differences between the intervention and control group, and using different outcome measures over the course of study follow-up.

References

    1. (UNAIDS) JUNPoHA. Global report: UNAIDS report on the global AIDS epidemic 2012. 2012.
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599. - PMC - PubMed
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012 - PMC - PubMed
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. The New England journal of medicine. 2012 - PubMed
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174. - PMC - PubMed

Publication types

MeSH terms

Substances